DiaMedica Therapeutics (DMAC) said Monday it has entered into definitive agreements to raise $30.1 million via a private placement of shares led by current investors.
DiaMedica said it will issue about 8.6 million shares at $3.50 per share.
The private placement is expected to close on or about Wednesday, the company said.
Funds will back DiaMedica's operations for over two years and support milestones including the submission of an investigational new drug application in the US for preeclampsia and fetal growth restriction and a phase 2b trial to further assess DM199 in both indications, subject to approval of the investigational new drug application, the company said.
Price: 4.20, Change: +0.02, Percent Change: +0.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.